Approval · Notice of Compliance 10240 · 2009
MUSE: Notice of Compliance 10240
Issued June 5, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10240
- Date
- June 5, 2009
- Company
- Paladin Labs Inc
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Prostaglandin
Products in this notice
Medicinal ingredients
- ALPROSTADIL 125 MCG per SUP
- ALPROSTADIL 250 MCG per SUP
- ALPROSTADIL 500 MCG per SUP
- ALPROSTADIL 1,000 MCG per SUP